Heron Therapeutics, Inc. (HRTX)
|52 Week Range||0.93-4.68|
|1y Target Est||-|
|DCF Unlevered||HRTX DCF ->|
|DCF Levered||HRTX LDCF ->|
|Debt / Equity||-397.43%||Strong Sell|
Upgrades & Downgrades
Latest HRTX news
Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say
15 August 2023
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wa...
Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript
14 August 2023
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Jeff Cohen - Executive Director, Assistant General Counsel and Assistant Secret...
Best Penny Stocks To Buy This Week? 3 To Watch Now
24 July 2023
Are you looking for the best penny stocks to buy now? There are plenty to choose from, and how you approach the stock market today will help determine your strategy.
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
11 May 2023
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.63 per share a year ago.
Why Heron Therapeutics Stock Has Been on Fire This Week
6 April 2023
Monday, Heron announced the appointment of Craig Collard as Chief Executive Officer and Adam Morgan as Chairman. These two executives will replace outgoing CEO and Chairman Barry Quart.
Why Shares of Heron Therapeutics Jumped Thursday
6 April 2023
Heron's cash position remains a concern. Zynrelef, the company's top-selling therapy for postoperative pain relief, had 2022 sales that were up 362%.
Heron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call Transcript
23 March 2023
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart –...
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
23 March 2023
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March ...
10 March 2023
SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class trea...